WallStreetZenWallStreetZen

NASDAQ: LAB
Standard Biotools Inc Stock Forecast, Predictions & Price Target

Analyst price target for LAB

Based on 1 analyst offering 12 month price targets for Standard Biotools Inc.
Min Forecast
$4.00+59.36%
Avg Forecast
$4.00+59.36%
Max Forecast
$4.00+59.36%

Should I buy or sell LAB stock?

Based on 1 analyst offering ratings for Standard Biotools Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LAB stock forecasts and price targets.

LAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-07-12

1 of 1

Forecast return on equity

Is LAB forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is LAB forecast to generate an efficient return on assets?

LAB revenue forecast

What is LAB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$103.0M-2.07%
Avg 2 year Forecast
$120.2M+14.29%
Avg 3 year Forecast
$146.4M+39.2%
LAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LAB revenue growth forecast

How is LAB forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
11.27%
Industry
4.94%
Market
7.56%
LAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LAB vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
LAB$2.45$4.00+63.27%Strong Buy
NVTA$0.51$0.40-21.57%Strong Sell
BDSX$1.50N/AN/A
FONR$19.55N/AN/A
GTH$3.69N/AN/A

Standard Biotools Stock Forecast FAQ

Is Standard Biotools Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LAB) stock is to Strong Buy LAB stock.

Out of 1 analyst, 1 (100%) are recommending LAB as a Strong Buy, 0 (0%) are recommending LAB as a Buy, 0 (0%) are recommending LAB as a Hold, 0 (0%) are recommending LAB as a Sell, and 0 (0%) are recommending LAB as a Strong Sell.

If you're new to stock investing, here's how to buy Standard Biotools stock.

What is LAB's revenue growth forecast for 2023-2025?

(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of 11.27% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.56%.

Standard Biotools's revenue in 2023 is $105,173,000.On average, 1 Wall Street analysts forecast LAB's revenue for 2023 to be $8,177,688,605, with the lowest LAB revenue forecast at $8,177,688,605, and the highest LAB revenue forecast at $8,177,688,605. On average, 1 Wall Street analysts forecast LAB's revenue for 2024 to be $9,543,283,207, with the lowest LAB revenue forecast at $9,543,283,207, and the highest LAB revenue forecast at $9,543,283,207.

In 2025, LAB is forecast to generate $11,623,433,124 in revenue, with the lowest revenue forecast at $11,623,433,124 and the highest revenue forecast at $11,623,433,124.

What is LAB's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: LAB) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 0.09%.

What is LAB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LAB price target, the average LAB price target is $4.00, with the highest LAB stock price forecast at $4.00 and the lowest LAB stock price forecast at $4.00.

The Wall Street analyst predicted that Standard Biotools's share price could reach $4.00 by Jul 12, 2024. The average Standard Biotools stock price prediction forecasts a potential upside of 63.27% from the current LAB share price of $2.45.

What is LAB's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: LAB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.